Guselkumab (TREMFYA®)

Selected References:

- Anderson PO. 2021. Monoclonal antibodies during breastfeeding. Breastfeed Med. *16*(8): 591-593.
- Dernoncourt A., et al. 2023. Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase®). BioDrugs. 37(1):73-87.
- Jeong YD, et al. 2025. Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study. Int Arch Allergy Immunol. 186(6):579-593.
- Kimball AB. 2020. Pregnancy outcomes in women exposed to guselkumab: Experience from the clinical development program. J Am Acad Dermatol. 83(6):AB27.
- Lin CB, Geldhof A, Ballina MR, Patel H. Fakharzadeh S, Li H. Pregnancy outcomes in women exposed to guzelkumab: Review of cases reported to the manufacturer's global safety database. BJD 2024;191[Suppl 3]:iii38-iii39 https://academic.oup.com/bjd/article/191/Supplement_3/ljae360.077/7916181
- Mahadevan U, et al. 2025. Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 23(11S):S1-S60.
- McMullan P et al. 2024. Safety of dermatologic medications in pregnancy and lactation: An Update-Part I: Pregnancy. *Journal of the American Academy of Dermatology*.
- Owczarek W, et al. 2020. The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines. Postepy Dermatol Alergol. 37(6):821-830.
- Tremfya® Prescribing Information. Available online at http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf. Accessed on May 28, 2024.
- Wolfe C et al., 2024. A Retrospective Review of Pregnancies in our Psoriasis Biologics Cohort. *Clinical and Experimental Dermatology*. llae106.
- Yeung J, et al. 2020. Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper. J Cutan Med Surg. 24(1_suppl):3S-14S.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Guselkumab (TREMFYA®)

Selected References:

- Aronne LJ. 1998. Obesity. Womens Health Issues 82(1):161- 181.
- Chang JJ, Lathi RB, Kim SH. 2020. A retrospective study examining phentermine on preconception weight loss and pregnancy outcomes. Endocrine Practice;26(9):990-996. https://doi.org/10.4158/EP-2019-0609
- Food and Drug Administration. 2012. Prescribing information for ADIPEX-P®. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf . Accessed 21 July 2026.
- Food and Drug Administration. 2013. Prescribing information for SUPRENZATM. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202088s005lbl.pdf. Accessed 21 July 2026.
- Food and Drug Administration. 2023. Prescribing information for Qsymia®. Available at https://qsymia.com/patient/include/media/pdf/prescribing-information.pdf. Accessed 21 July 2026.
- Hale TW. 2008. Medications and Mothers' Milk, 13th ed. Amarillo, TX: Hale Publishing.
- Johnson KA, et al. 1998. Pregnancy outcome of women exposed to Fen/Phen [abstract]. Organization of Teratology Information Specialists Annual Meeting, June 1998.
- Jones KL, et al. 2002. Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine. Teratology 65:125-130.
- No authors listed. 2013. Topiramate + phentermine. An excessively dangerous appetite-suppressant combination. Prescrire Int 22(136):61-4.
- Robert E, et al. 1995. Neural tube defects and maternal weight reduction in early pregnancy. Reprod Toxicol 9(1):57-59.
- Silverstone, T. 1982. Drugs and Appetite. New York: Academic Press.
- Stein AD, et al. 1995. Third-trimester pregnancy weight gain and intrauterine growth: The Dutch Famine Birth Cohort Study. Hum Biol 67(1):135-150.
- Winick M. 1989. Nutrition, Pregnancy, and Early Infancy. Baltimore: Williams & Wilkins.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Guselkumab (TREMFYA®)

Selected References:

- American College of Obstetricians and Gynecologists Committee on Genetics. 2020. Management of women with phenylalanine hydroxylase deficiency (phenylketonuria). Obstet Gynec 135(4): e167-e-170.
- Alabdulrazzaq F, Koren G. 2012. Topical corticosteroid use during pregnancy. Can Fam Physician 58(6): 643–644.
- Alhussien AH, et al. 2018. Safety of intranasal corticosteroid sprays during pregnancy: an updated review. Eur Arch Otorhinolaryngol 275(2): 325–333.
- Battista MC, et al. 2016. Maternal inhaled fluticasone propionate intake during pregnancy is detected in neonatal cord blood. Bioanalysis, 8(14): 1441–1450.
- Bjørn AMB, et al. 2015. Use of inhaled and oral corticosteroids in pregnancy and the risk of malformations or miscarriage. Basic Clin Pharmacol Toxicol 116(4): 308–314.
- Blais L, et al. 2009. High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations. J Allergy Clin Immunol, 124(6): 1229-1234.e4.
- Charlton RA, et al. 2015. Safety of fluticasone propionate prescribed for asthma during pregnancy: A UK population-based cohort study. J Allergy Clin Immunol Pract 3(5): 772-9.e3.
- Clifton VL, et al. 2006. Effect of inhaled glucocorticoid treatment on placental 11β-hydroxysteroid dehydrogenase type 2 activity and neonatal birthweight in pregnancies complicated by asthma. Aust N Z J Obstet Gynaecol 46(2): 136–140.
- Cossette B, et al. 2014. Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy. Ann Allergy Asthma Immunol 112(5): 459–464.
- Dombrowski MP, et al. 2008. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy. Obstet Gynecol, 111(2 Pt 1): 457-464.
- Edwards M J, et.al. 2003. Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy. Am J Med Genet 120A(4): 459–463.
- Ellegård EK, et al. 2001. Fluticasone propionate aqueous nasal spray in pregnancy rhinitis. Clin Otolaryngol Allied Sci 26(5): 394–400.
- Källén B, Otterblad Olausson P. 2007. Use of anti-asthmatic drugs during pregnancy. 3. Congenital malformations in the infants. Eur J of Clin Pharmacol, 63(4): 383–388.
- Middleton PG ,et al. 2020. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J 55(2): 1901208.
- Mygind N, et al. 2001. Mode of action of intranasal corticosteroids. J Allergy Clin Immunol 108(1 Suppl): S16-25.
- Park-Wyllie L, et.al. 2000. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratol, 62(6): 385–392.
- Pradat P, et al. 2003. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin

Mol Teratol 67(12): 968–970.

- Rahimi R, et al. 2006. Meta-analysis finds use of inhaled corticosteroids during pregnancy safe: a systematic meta-analysis review. Hum Exp Toxicol 25(8): 447–452.
- Robijn AL, et al. 2019. Inhaled corticosteroid use during pregnancy among women with asthma: A systematic review and meta-analysis. Clin Exp Allergy 49(11): 1403–1417.
- Rocklin R. 2011. Asthma, asthma medications and their effects on maternal/fetal outcomes during pregnancy. Reprod Toxicol 32(2): 150.
- Rodríguez-Pinilla E, Martínez-Frías ML. 1998. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratol, 58(1): 2–5.
- Tegethoff M, et.al. 2012. Inhaled glucocorticoids during pregnancy and offspring pediatric diseases: a national cohort study. Am J Respir Crit Care Med 185(5): 557–563.
- Van Zutphen AR, et al. 2015. Maternal asthma medication use during pregnancy and risk of congenital heart defects: Asthma Medication Use and Congenital Heart Defects. Birth Defects Res A Clin Mol Teratol 103(11): 951–961.
- Zaidi S, et al. 2019. Fetal concentrations of budesonide and fluticasone propionate: A study in mice. AAPS J 21(4): 53.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Guselkumab (TREMFYA®)

Selected References:

- ANI Pharmaceuticals. 2024. Fenoprofen product labeling. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm. Accessed 16 June 2026.
- Choi E-Y, et al. 2023. Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory drugs during early pregnancy in South Korea: a nationwide cohort study. PLoS Med, 20(2):e1004183.

- Dawood MY. 1993. Nonsteroidal antiinflammatory drugs and reproduction. Am J Obstet Gynecol, 169(5):1255-1265.
- Daniel S, et al. 2012. Major Malformations Following Exposure to Nonsteroidal Antiinflammatory Drugs During the First Trimester of Pregnancy. J Rhuematol 39(11) 2163-2169.
- Daniel S, et al. 2014. Fetal exposure to nonsteroidal anti-inflammatory drugs and spontaneous abortion. Can Med Assoc J 186(5):E177-E182.
- Daniel S, et al. 2015. NSAIDs and spontaneous abortions – true effect or an indication bias? Br J Clin Pharmacol, 80(4):750-754.
- Dathe K, et al. 2018. No evidence of adverse pregnancy outcome after exposure to ibuprofen in the first trimester—Evaluation of the national Embryotox cohort. Reproductive Toxicology, 79: 32-38.
- Ericson A and Kallen BA. 2001. Nonsteroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol, 15:371-
- Janssen NM and Genta MS. 2000. The effects of immunosuppressive and anti-inflammatory medication on fertility, pregnancy, and lactation. Arch Intern Med, 160:610-619.
- Nezvalova-Henriksen K et al. 2013. Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective study. BJOG, 120(8):948-959.
- Nielsen GL, et al. 2001. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ, 322(7281):266-270.
- Nielsen GL, et al. 2004. Danish group reanalyses miscarriage in NSAID users. BMJ, 328(7431):109.
- U.S. Food and Drug Administration. 2020. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Drug Safety Communication – Avoid Use of NSAIDs in Pregnancy at 20 Weeks or Later. Available at: https://www.fda.gov/safety/medical-product-safety-information/nonsteroidal-anti-inflammatory-drugs-nsaids-drug-safety-communication-avoid-use-nsaids-pregnancy-20. Accessed 16 June 2026.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Guselkumab (TREMFYA®)

Selected References:

- American College of Obstetricians and Gynecologists (ACOG). 2019. ACOG Practice Bulletin No. 203 Summary: Chronic Hypertension in Pregnancy. Obstet Gynecol; 133(1): 215-219.
- Davis RL, et al. 2011. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf; 20:138-145.
- Kubota K, et al. 2023. Alpha/beta- and beta-blocker exposure in pregnancy and the risk of neonatal hypoglycemia and small for gestational age. Circ J; 87: 569-577.
- Lennestal R, et al. 2009. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol; 65(6): 615-625.
- McCowan LM, et al. 1996. Perinatal morbidity in chronic hypertension. Br J Obstet Gynecol; 103:123–129.
- Ray JG, et al. 2001. McMaster outcome study of hypertension in pregnancy. Early Hum Dev; 64:129–143.
- Rey E, Couturier A. 1994. The prognosis of pregnancy in women with chronic hypertension. Am J Obst Gynecol; 181:410–416.
- Sibal BM, et al. 2000. Preterm delivery in women with pregestational diabetes or chronic hypertension relative to women with uncomplicated pregnancies. The National Institute of Child Health and Human Development – Fetal Medicine Units Network. Am J Obst Gynecol; 183:1520–1524.
- Tanaka K, et al. 2016. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J; 80: 2221-2226.
- Waylis Therapeutics LLC. 2025. Coreg Product Label. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm. Accessed 12 June 2026.
- Yakoob MY, et al. 2013. The risk of congenital malformations associated with exposures to beta-blockers early in pregnancy: A meta-analysis. Hypertension; 62(2): 375-381.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.